NO20055210L - Inhibitorproteiner av en protease og anvendelse derav - Google Patents

Inhibitorproteiner av en protease og anvendelse derav

Info

Publication number
NO20055210L
NO20055210L NO20055210A NO20055210A NO20055210L NO 20055210 L NO20055210 L NO 20055210L NO 20055210 A NO20055210 A NO 20055210A NO 20055210 A NO20055210 A NO 20055210A NO 20055210 L NO20055210 L NO 20055210L
Authority
NO
Norway
Prior art keywords
protease
inhibitor protein
sequence
chimeric inhibitor
purified
Prior art date
Application number
NO20055210A
Other languages
English (en)
Other versions
NO334459B1 (no
NO20055210D0 (no
Inventor
David Deperthes
Sylvain Cloutier
Original Assignee
Univ Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lausanne filed Critical Univ Lausanne
Publication of NO20055210D0 publication Critical patent/NO20055210D0/no
Publication of NO20055210L publication Critical patent/NO20055210L/no
Publication of NO334459B1 publication Critical patent/NO334459B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører et kimert hemmerprotein til en protease som omfatter en hemmende polypeptidlignende sekvens, og minst en polypeptidlignende sekvens til et substrat-enzyminteraksjonssete som er spesifikt for en protease. Andre temaer i oppfinnelsen er å tilveiebringe en renset og isolert DNA-sekvens som koder for det kimere hemmerproteinet til en protease, en ekspresjonsvektor som er karakterisert ved at den omfatter nevnte, rensede og isolerte DNA-sekvens, en eukaryot eller prokaryot vertscelle transformert med denne ekspresjonsvektor og en fremgangsmåte for å produsere et kimert hemmerprotein.
NO20055210A 2003-04-04 2005-11-04 Kallikrein inhibitor, DNA, vektor, vertcelle, farmasøytisk sammensetning, kit, anvendelse samt fremgangsmåte for fremstilling. NO334459B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46034503P 2003-04-04 2003-04-04
PCT/IB2004/001040 WO2004087912A1 (en) 2003-04-04 2004-04-05 Inhibitor proteins of a protease and use thereof

Publications (3)

Publication Number Publication Date
NO20055210D0 NO20055210D0 (no) 2005-11-04
NO20055210L true NO20055210L (no) 2005-12-23
NO334459B1 NO334459B1 (no) 2014-03-10

Family

ID=33131923

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055210A NO334459B1 (no) 2003-04-04 2005-11-04 Kallikrein inhibitor, DNA, vektor, vertcelle, farmasøytisk sammensetning, kit, anvendelse samt fremgangsmåte for fremstilling.

Country Status (19)

Country Link
US (1) US8975370B2 (no)
EP (1) EP1616007B1 (no)
JP (1) JP4754478B2 (no)
KR (1) KR101296367B1 (no)
CN (1) CN1798838B (no)
AU (1) AU2004225718B2 (no)
BR (1) BRPI0409557B8 (no)
CA (1) CA2521410C (no)
CY (1) CY1114526T1 (no)
DK (1) DK1616007T3 (no)
ES (1) ES2431548T3 (no)
IL (1) IL171158A (no)
MX (1) MXPA05010574A (no)
NO (1) NO334459B1 (no)
PL (1) PL1616007T3 (no)
PT (1) PT1616007E (no)
SG (1) SG161106A1 (no)
SI (1) SI1616007T1 (no)
WO (1) WO2004087912A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2902501B1 (en) 2002-01-28 2020-04-15 Life Technologies Corporation Preparing crude biological extracts using protease, suitable for preparing cDNA
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
CN110522905A (zh) * 2008-01-21 2019-12-03 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
EP2955233A1 (en) 2008-12-19 2015-12-16 Life Technologies Corporation Proteinase K inhibitors, methods and compositions therefor
AU2010222537B2 (en) * 2009-03-10 2016-06-30 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
SG195083A1 (en) * 2011-05-26 2013-12-30 Baxter Int Solid phase-bound elastase-binding assay for the measurement of alpha1,-antitrypsin activity
CN103044542B (zh) * 2012-08-17 2015-08-19 常熟理工学院 鲫鱼卵中丝氨酸蛋白酶抑制剂及其基因和应用
CN117169519B (zh) * 2023-10-26 2024-01-30 艾康生物技术(杭州)有限公司 用于检测样本中tt3和/或tt4的解离剂和试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ATE226636T1 (de) * 1989-03-06 2002-11-15 Univ Texas Serpin-resistenter t-pa; mutanten; gene
US5612194A (en) * 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
US5723316A (en) 1989-06-23 1998-03-03 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having chymase inhibiting activity
US5827662A (en) 1989-06-23 1998-10-27 The Trustees Of The University Of Pennsylvania Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE275583T1 (de) 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US6284873B1 (en) 1999-03-12 2001-09-04 Hybritech Incorporated Complex of human kallikrein 2 (hK2) and protease inhibitor-6 (PI-6) in prostate tumor tissue and methods of using the complex

Also Published As

Publication number Publication date
KR101296367B1 (ko) 2013-08-14
SG161106A1 (en) 2010-05-27
WO2004087912A8 (en) 2005-01-20
JP4754478B2 (ja) 2011-08-24
EP1616007A1 (en) 2006-01-18
EP1616007B1 (en) 2013-07-24
MXPA05010574A (es) 2006-03-09
BRPI0409557A (pt) 2006-04-18
US8975370B2 (en) 2015-03-10
PL1616007T3 (pl) 2013-12-31
AU2004225718B2 (en) 2009-11-05
DK1616007T3 (da) 2013-10-28
ES2431548T3 (es) 2013-11-26
SI1616007T1 (sl) 2013-12-31
CY1114526T1 (el) 2016-10-05
KR20060010740A (ko) 2006-02-02
CN1798838B (zh) 2012-01-04
US20060269536A1 (en) 2006-11-30
CA2521410C (en) 2014-06-03
PT1616007E (pt) 2013-10-28
CN1798838A (zh) 2006-07-05
NO334459B1 (no) 2014-03-10
BRPI0409557B1 (pt) 2019-07-23
NO20055210D0 (no) 2005-11-04
IL171158A (en) 2011-05-31
WO2004087912A1 (en) 2004-10-14
CA2521410A1 (en) 2004-10-14
JP2006523097A (ja) 2006-10-12
AU2004225718A1 (en) 2004-10-14
BRPI0409557B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
FI961886A (fi) Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit
NO20062315L (no) Minimal DNA-sekvens som virker som en kromatinisolator og dets anvendelse i proteinekspresjon
NO20052928L (no) Nye kjemiske forbindelser
WO2005047511A3 (en) Bacterial expression of protease inhibitors and variants thereof
Hsieh et al. Total synthesis of homogeneous variants of hirudin P6: a post‐translationally modified anti‐thrombotic leech‐derived protein
DK1606317T3 (da) Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
ATE398676T2 (de) Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
MY120693A (en) Human bikunin
NO20051451L (no) Pyrimidinderivater og deres anvendelse som CB2 modulatorer
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20005637D0 (no) Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav
DE60330841D1 (de) Überexpression von extremozymgenen in pseudomonas und nahe verwandte bakterien
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
NO20070640L (no) Forbedrede aprotininvananter
DK1763586T3 (da) Ny sekvens til forbedring af ekspressionen af nukleinsyre
ATE387220T1 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
DK1756273T3 (da) Signalpeptid til frembringelse af et polypeptid
ATE532861T1 (de) Expressionsvektor
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
BR0313083A (pt) moléculas de adamts4 modificadas,polinucleotìdeo, vetor, processos para produção, composição farmacêutica, bem como uso das mesmas
WO2006090282A3 (en) Recombinant inhibitor proteins of an hk14 protease and use thereof
ATE486127T1 (de) Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf